Patient Characteristics
| Characteristic | n or median | % or range |
| Patients | 102 | 100% |
| American Joint Committee on Cancer Stage | Conventional staging/PET staging | |
| IA | 5/5 | 4.9%/4.9% |
| IB | 53/45 | 52.0%/44.1% |
| IIA | 0/0 | 0.0%/0.0% |
| IIB | 6/4 | 5.9%/3.9% |
| IIIA | 1/1 | 1.0%/1.0% |
| IIIB | 35/43 | 34.3%/42.2% |
| IV* | 2/4 | 2.0%/3.9% |
| Primary treatment modality | ||
| Chemotherapy alone | 1 | 1.0% |
| RT alone | 8 | 7.8% |
| Chemoradiation therapy (without surgery) | 18 | 17.6% |
| Surgery alone | 29 | 28.4% |
| Surgery followed by RT | 35 | 34.3% |
| Surgery followed by chemoradiation therapy | 11 | 10.8% |
| Complete histopathology report from biopsy or local excision | 82 | 86.2% |
| Lymphovascular space invasion | 19 | 23.2% |
| Positive resection margin or biopsy only | 44 | 53.7% |
| Age (y) | 77 | 36–99 |
| Size of primary (mm) | 13 | 0–70 |
| SUVmax | 10.1 | 1.7–30.1 |
| SUVmean | 4.8 | 1.2–9.9 |
| Metabolic volume (mm3) | 11,769 | 597–260,165 |
| Median biologically effective dose of RT | 60 Gy | Interquartile (59.5–60 Gy) |
↵* Two patients with suggestive (but not proven) stage IV disease on conventional imaging who were otherwise fit for curative-intent treatment underwent 18F-FDG PET to clarify disease status.